Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$64.46
-0.4%		$63.39
$42.52
▼
$68.64
$132.14B0.237.65 million shs6.54 million shs
BXP, Inc. stock logo
BXP
BXP
$64.35
-2.1%		$68.61
$49.72
▼
$79.33
$10.50B1.011.09 million shs1.44 million shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
▼
$0.04
N/A26.97100 shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.26%-4.58%-0.45%+13.17%+36.43%
BXP, Inc. stock logo
BXP
BXP
-2.23%-4.11%-5.14%-2.73%-11.08%
ERGO
Entia Biosciences
0.00%0.00%+300.00%+33.33%+700.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$64.46
-0.4%		$63.39
$42.52
▼
$68.64
$132.14B0.237.65 million shs6.54 million shs
BXP, Inc. stock logo
BXP
BXP
$64.35
-2.1%		$68.61
$49.72
▼
$79.33
$10.50B1.011.09 million shs1.44 million shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
▼
$0.04
N/A26.97100 shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.26%-4.58%-0.45%+13.17%+36.43%
BXP, Inc. stock logo
BXP
BXP
-2.23%-4.11%-5.14%-2.73%-11.08%
ERGO
Entia Biosciences
0.00%0.00%+300.00%+33.33%+700.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.56
Moderate Buy$66.062.47% Upside
BXP, Inc. stock logo
BXP
BXP
2.58
Moderate Buy$75.2816.98% Upside
ERGO
Entia Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BXP, VEC, ERGO, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
BXP, Inc. stock logo
BXP
BXP
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$64.00 ➝ $68.00
9/1/2026
BXP, Inc. stock logo
BXP
BXP
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$77.00 ➝ $82.00
8/27/2026
BXP, Inc. stock logo
BXP
BXP
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$90.00 ➝ $88.00
8/25/2026
BXP, Inc. stock logo
BXP
BXP
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$61.00 ➝ $70.00
8/25/2026
BXP, Inc. stock logo
BXP
BXP
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$79.00 ➝ $87.00
8/18/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/12/2026
BXP, Inc. stock logo
BXP
BXP
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
8/5/2026
BXP, Inc. stock logo
BXP
BXP
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$76.00
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform ➝ Strong-Buy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Buy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.73$8.11 per share7.95$9.09 per share7.09
BXP, Inc. stock logo
BXP
BXP
$3.52B2.92$8.00 per share8.04$48.49 per share1.33
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5414.2010.010.3118.87%66.90%14.74%10/29/2026 (Estimated)
BXP, Inc. stock logo
BXP
BXP
$276.80M$1.8634.609.012.468.44%3.88%1.16%10/27/2026 (Estimated)
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest BXP, VEC, ERGO, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
7/28/2026Q2 2026
BXP, Inc. stock logo
BXP
BXP
$0.4031$0.43+$0.0269$0.43$858.07 million$895.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.523.91%+1.61%55.51%17 Years
BXP, Inc. stock logo
BXP
BXP
$2.804.35%-3.04%150.54%N/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A

Latest BXP, VEC, ERGO, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/17/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.34%7/2/20267/2/20268/3/2026
6/17/2026
BXP, Inc. stock logo
BXP
BXP
quarterly$0.704.22%6/30/20266/30/20267/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
BXP, Inc. stock logo
BXP
BXP
2.07
3.91
3.91
ERGO
Entia Biosciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
BXP, Inc. stock logo
BXP
BXP
98.72%
ERGO
Entia Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
BXP, Inc. stock logo
BXP
BXP
1.50%
ERGO
Entia Biosciences
28.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
BXP, Inc. stock logo
BXP
BXP
780159.66 million157.27 millionOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable

Recent News About These Companies

Careology partners with Entia to offer at home blood monitoring
March 18, 2025  |  laingbuissonnews.comL
Careology and Entia join forces to transform cancer care
March 17, 2025  |  pharmatimes.comP
The Best Ergonomic Keyboards for 2024
October 4, 2024  |  pcmag.comP
INTEGRA Biosciences' pipettes are endorsed by ergonomics champion iHEALTH 360
August 1, 2024  |  msn.comhttps://www.msn.com/en-gb/money/other/integra-biosciences-pipettes-are-endorsed-by-ergonomics-champion-ihealth-360/ar-BB1r1Z86
Entia at-home full blood count analyser to be deployed at NHS trusts
May 20, 2024  |  digitalhealth.netD
Breakthrough in Cancer Care After Entia Gets Go-Ahead for World’s First At-Home Blood Monitoring Solution for Patients
May 13, 2024  |  pharmiweb.comP
Hdfc Ergo
April 23, 2024  |  moneycontrol.comhttps://www.moneycontrol.com/news/tags/hdfc-ergo.html
Digital Health Spotlight: Entia looks to improve cancer care at home
August 18, 2023  |  digitalhealth.netD
Cancer monitoring platform Entia secures $20m funding boost
July 26, 2023  |  news.sky.comN
Singing this song on Holy Thursday can purify your soul (and save you time in Purgatory)
April 7, 2023  |  catholicnewsagency.comC
Top HDFC ERGO Health Insurance Plans
April 6, 2023  |  forbes.comhttps://www.forbes.com/advisor/in/health-insurance/hdfc-ergo-health-insurance/
Cooler Master Hybrid 1 Ergo Gaming Chair Review
February 25, 2023  |  ign.comI
Entia Biosciences, Inc. (ERGO)
October 3, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/quote/ERGO/history?p=ERGO
HDFC ERGO partners with HDFC Life, to offer all-round protection to customers
September 25, 2022  |  livemint.comhttps://www.livemint.com/news/india/hdfc-ergo-partners-with-hdfc-life-to-offer-all-round-protection-to-customers-11663943351599.html
Entia Biosciences Inc (ERGO)
January 7, 2022  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/ergo/dividend-history?random=61d597807b6b9
Entia Biosciences Dividend Per Share (TTM)
December 26, 2021  |  ycharts.comY
Entia Biosciences EPS Diluted (5 Year Growth)
December 21, 2021  |  ycharts.comY
Entia Biosciences Year to Date Total Returns (Daily)
December 20, 2021  |  ycharts.comY
Medtech firm Entia raises $12m for ‘virtual oncology solution’
October 11, 2021  |  pharmatimes.comP
BGF invests $12m in virtual oncology business Entia
October 11, 2021  |  angelnews.co.ukA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$64.46 -0.23 (-0.35%)
Closing price 09/9/2026 03:59 PM Eastern
Extended Trading
$64.56 +0.09 (+0.15%)
As of 04:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

BXP stock logo

BXP NYSE:BXP

$64.35 -1.39 (-2.11%)
Closing price 09/9/2026 03:59 PM Eastern
Extended Trading
$64.37 +0.02 (+0.03%)
As of 09/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Properties, Inc. (NYSE: BXP) (BXP or the Company) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by joint ventures, BXP's portfolio totals 53.3 million square feet and 188 properties, including 10 properties under construction/redevelopment. BXP's properties include 167 office properties, 14 retail properties (including two retail properties under construction/redevelopment), six residential properties (including one residential property under construction) and one hotel. BXP is well-known for its inhouse building management expertise and responsiveness to clients' needs. BXP holds a superior track record of developing premium Central Business District (CBD) office buildings, successful mixed-use complexes, suburban office centers and build-to-suit projects for a diverse array of creditworthy clients. BXP actively works to promote its growth and operations in a sustainable and responsible manner. BXP has earned a twelfth consecutive GRESB Green Star recognition and the highest GRESB 5-star Rating. BXP, an S&P 500 company, was founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde and became a public company in 1997.

Entia Biosciences OTCMKTS:ERGO

$0.0008 0.00 (0.00%)
As of 09/8/2026

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas